Regulatory product record
ZENRELIA
Product identity, ingredients and source provenance from the regulatory catalogue. Linked clinical evidence has a separate review status.
Product identity
- Brand name
- ZENRELIA
- DIN
- 02552051
- DPD drug code
- 104075
- Regulatory category
- APPROVED_VET_DRUG
- Market status
- MARKETED
- Route(s)
- ORAL
- Pharmaceutical form(s)
- TABLET
- Ingredients
- ILUNOCITINIB (4.8 MG)
- Species (DPD record)
- DOGS
- Company
- ELANCO CANADA LIMITED (DIN owner)
Source and provenance
- Source dataset
- health_canada_dpd_marketed
- Source snapshot date
- Not available in this source
- Source record key
- 104075
- Archive fingerprint (SHA-256)
- 85cc3ce208af3aa57018c3d14d83f90220c436baef7455384b6d48d9774e1c88
Linked clinical reference
Clinical entries are linked through the active molecule. Check their species, formulation, source and review status separately from this product record.
Clinical evidence
Dose regimens0
No dose regimens recorded for this species selection.
Adverse effects105
These are counts of spontaneously reported events, not proven adverse effects, causal relationships, or incidence rates.
Bars compare report counts within each species; they do not show incidence.
More reportsFewer reportsDog
- Lack of efficacy - NOS321 reports
- Lethargy (see also Central nervous system depression in Neurological)230 reports
- Diarrhoea196 reports
- Vomiting169 reports
- Neutropenia168 reports
- Decreased haematocrit132 reports
- Elevated serum alkaline phosphatase (ALP)119 reports
- Lymphopenia113 reports
- Elevated alanine aminotransferase (ALT)99 reports
- Leucopenia NOS97 reports
- Other abnormal test result NOS93 reports
- Anaemia NOS90 reports
Cat
- Accidental exposure1 reports
- Distress1 reports
- Elevated temperature1 reports
- Increased heart rate1 reports
- Increased respiratory rate1 reports
Literature references8
References are linked to this drug. Species applicability is not recorded here, so the species filter does not narrow this list. Imported dates do not retain their original precision; confirm dates in the original citation.
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.
Study summary not available in the imported record. Open the original citation to review the study.
- Pharmacokinetics of Ilunocitinib, a New Janus Kinase Inhibitor, in Dogs.
Study summary not available in the imported record. Open the original citation to review the study.
- Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial.
Study summary not available in the imported record. Open the original citation to review the study.
- Immunologic response to first booster vaccination in dogs treated with zenrelia™ (ilunocitinib tablets) at up to three times the recommended therapeutic dose compared to untreated controls.
Study summary not available in the imported record. Open the original citation to review the study.
- Response to primary canine core vaccination in 10-month-old seronegative dogs treated with three times the recommended therapeutic dose of Ilunocitinib tablets (Zenrelia™).
Study summary not available in the imported record. Open the original citation to review the study.
Sources: PubMed, National Library of Medicine; openFDA, U.S. Food and Drug Administration.